{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:35:52Z","timestamp":1793810152965,"version":"4.6.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:56:36Z","timestamp":1741308996000},"page":"565-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular testing in urinary cytology specimens: Current status and future directions"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-4399","authenticated-orcid":false,"given":"Fei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Simsir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.02.009_bib0001","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0002","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0003","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrurol.2018.2","article-title":"A practical guide to bladder cancer pathology","volume":"15","author":"Comperat","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0006","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0008","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/ijms21072514","article-title":"Extracellular vesicles as signaling mediators and disease biomarkers across biological barriers","volume":"21","author":"Simeone","year":"2020","journal-title":"Int J Molecul Sci"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0009","first-page":"59","article-title":"The Paris System for reporting urinary cytology: an updated review","volume":"3","author":"Chen","year":"2023","journal-title":"J Clin Transl Pathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncy.22782","article-title":"Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: a major cancer center experience","volume":"132","author":"Alhamar","year":"2024","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14737159.2020.1699791","article-title":"Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers","volume":"20","author":"Lopez-Beltran","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0012","series-title":"The Paris System for reporting urinary cytology","author":"Wojcik","year":"2022"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0013","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cncy.22061","article-title":"Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value below 0.7 for positive for high-grade urothelial carcinoma and suspicious for high-grade urothelial carcinoma in urine cytology specimens","volume":"127","author":"McIntire","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jasc.2014.11.002","article-title":"Subclassifying atypia in urine cytology: what are the helpful features?","volume":"4","author":"McCroskey","year":"2015","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41585-019-0184-4","article-title":"Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018","volume":"16","author":"Lotan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0016","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer - current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14737159.2019.1680284","article-title":"Liquid biopsy in the clinical management of bladder cancer: current status and future developments","volume":"20","author":"Kouba","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0018","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","volume":"86","author":"Nordentoft","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0020","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0021","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.005","article-title":"Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management","volume":"133","author":"Cheng","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0022","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00345-022-04061-9","article-title":"Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer","volume":"40","author":"Carrasco","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ebiom.2019.05.004","article-title":"Le Calvez-Kelm F: urinary promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer","volume":"44","author":"Avogbe","year":"2019","journal-title":"Ebiomedicine"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-3360-0_5","article-title":"Digital PCR: principles and applications","volume":"1392","author":"Kanagal-Shamanna","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-0716-3291-8_13","article-title":"Simplex droplet digital PCR assays for the detection of TERT promoter mutations in urine samples for the non-invasive diagnosis of urothelial cancer","volume":"2684","author":"Zvereva","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0026","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jtho.2022.11.006","article-title":"A clinician's guide to bioinformatics for next-generation sequencing","volume":"18","author":"Larson","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0027","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1007\/s12010-022-04234-7","article-title":"Identify potential urine biomarkers for bladder cancer prognosis using NGS data analysis and experimental validation","volume":"195","author":"Ren","year":"2023","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cncy.22410","article-title":"Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens","volume":"129","author":"Sun","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0031","first-page":"18","article-title":"Utility of urine cytology specimens for molecular profiling in detection of high-grade urothelial carcinoma","volume":"103","author":"Chen","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0032","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/cncy.21847","article-title":"Next-generation sequencing of urine specimens: a novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin","volume":"125","author":"Scott","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0033","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.21037\/tcr.2019.03.03","article-title":"Massively parallel sequencing of urinary DNA-the dawn of non-invasive bladder cancer detection and surveillance?","volume":"8","author":"Ward","year":"2019","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0034","article-title":"Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy","volume":"7","author":"Springer","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0035","doi-asserted-by":"crossref","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0036","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-12-3276","article-title":"A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine","volume":"19","author":"Kandimalla","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0037","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0038","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0039","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-017-3758-7","article-title":"DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells","volume":"17","author":"Tan","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0040","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JU.0000000000002748","article-title":"DNA methylation urine biomarkers test in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective clinical trial","volume":"208","author":"Territo","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0041","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1101\/gr.116863.110","article-title":"Application of microdroplet PCR for large-scale targeted bisulfite sequencing","volume":"21","author":"Komori","year":"2011","journal-title":"Genome Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0042","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark-a urinary biomarker assay for the detection of bladder cancer","volume":"9","author":"Feber","year":"2017","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0043","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12967-023-04811-2","article-title":"Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms","volume":"22","author":"Furuya","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0044","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2009.07.041","article-title":"Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples","volume":"58","author":"Renard","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0046","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","article-title":"Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0047","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/JU.0000000000003188","article-title":"A urine-based DNA methylation marker test to detect upper tract urothelial carcinoma: a prospective cohort study","volume":"209","author":"Ghoreifi","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0048","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12881-020-01050-w","article-title":"A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - design of the Urodiag(R) PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC)","volume":"21","author":"Roperch","year":"2020","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0049","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12885-016-2748-5","article-title":"Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer","volume":"16","author":"Roperch","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0050","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s12325-017-0518-7","article-title":"Clinical utility of cxbladder for the diagnosis of urothelial carcinoma","volume":"34","author":"Darling","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0051","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of cxbladder and adjudication of Atypical cytology and equivocal cystoscopy","volume":"76","author":"Konety","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0052","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/JU.0000000000003126","article-title":"Urinary analysis of FGFR3 and TERT gene mutations enhances performance of cxbladder tests and improves patient risk stratification","volume":"209","author":"Lotan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0053","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bju.15418","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert(R) bladder cancer monitor) for surveillance in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Cowan","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0054","doi-asserted-by":"crossref","first-page":"163 e1- e9","DOI":"10.1016\/j.urolonc.2021.08.017","article-title":"Xpert bladder cancer monitor in surveillance of bladder cancer: systematic review and meta-analysis","volume":"40","author":"Sharma","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0055","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00345-023-04350-x","article-title":"Diagnostic value of Xpert(R) BC detection, Bladder EpiCheck(R), UroVysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma","volume":"41","author":"Pycha","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0056","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00414-009-0402-3","article-title":"MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation","volume":"124","author":"Zubakov","year":"2010","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119948","article-title":"Long non-coding RNAs as new players in bladder cancer: lessons from pre-clinical and clinical studies","volume":"288","author":"Mirzaei","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0058","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7150\/jca.37006","article-title":"A panel of urinary long non-coding RNAs differentiate bladder cancer from urocystitis","volume":"11","author":"Yu","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0059","article-title":"Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer","volume":"39","author":"Wang","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0060","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2018.1470442","article-title":"Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression","volume":"7","author":"Clos-Garcia","year":"2018","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0061","doi-asserted-by":"crossref","first-page":"e12093","DOI":"10.1002\/jev2.12093","article-title":"Urinary extracellular vesicles: a position paper by the Urine Task Force of the International Society for Extracellular Vesicles","volume":"10","author":"Erdbrugger","year":"2021","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0062","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1701133","article-title":"Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires","volume":"3","author":"Yasui","year":"2017","journal-title":"Sci Adv"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0063","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14737159.2019.1665998","article-title":"Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies","volume":"20","author":"Zeuschner","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0064","first-page":"179","article-title":"Altered proteome of extracellular vesicles derived from bladder cancer patients urine","volume":"41","author":"Lee","year":"2018","journal-title":"Mol Cells"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.976407","article-title":"Alpha-2-macroglobulin as a novel diagnostic biomarker for human bladder cancer in urinary extracellular vesicles","volume":"12","author":"Lee","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0066","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0067","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0068","doi-asserted-by":"crossref","first-page":"484.e17","DOI":"10.1016\/j.urolonc.2023.06.013","article-title":"BTA stat(R), NMP22(R) BladderChek(R), UBC(R) rapid Test, and CancerCheck(R) UBC(R) rapid VISUAL as urinary marker for bladder cancer: final results of a German multicenter study","volume":"41","author":"Ecke","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0069","series-title":"Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer","author":"Chou","year":"2015"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369357","article-title":"Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO\/ICUD consensus","volume":"94","author":"Schmitz-Drager","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0071","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0302-2838(01)00015-X","article-title":"Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder","volume":"41","author":"Babjuk","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0072","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/modpathol.3800262","article-title":"ImmunoCyt\/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma","volume":"18","author":"Tetu","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0073","first-page":"651","article-title":"The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer","volume":"32","author":"Karaoglu","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0074","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-021-02796-4","article-title":"Diagnostic performance of Oncuria, a urinalysis test for bladder cancer","volume":"19","author":"Hirasawa","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.48083\/SBLR8004","article-title":"Urine-based cell-free DNA tests in urothelial cancer: additional value for clinical decision-making?","volume":"4","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Soc Int Urol J"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0076","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-23-0513","article-title":"Urinary tumor DNA MRD analysis to identify responders to Neoadjuvant immunotherapy in muscle-invasive bladder cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0077","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0078","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Jeffrey","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0079","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1158\/1078-0432.CCR-23-0367","article-title":"Evaluation of somatic mutations in urine samples as a noninvasive method for the detection and molecular classification of endometrial cancer","volume":"29","author":"Costas","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euo.2023.11.009","article-title":"A fully automated artificial intelligence system to assist pathologists' Diagnosis to predict histologically high-grade urothelial carcinoma from digitized urine cytology slides using Deep learning","volume":"7","author":"Tsuji","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0081","article-title":"Development and validation of an artificial intelligence-based model for detecting urothelial carcinoma using urine cytology images: a multicentre, diagnostic study with prospective validation","volume":"71","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0082","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1038\/s41598-024-52728-7","article-title":"Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer","volume":"14","author":"Demir","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0083","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bju.15518","article-title":"Urine cell image recognition using a deep-learning model for an automated slide evaluation system","volume":"130","author":"Kaneko","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0084","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bju.15382","article-title":"Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test","volume":"129","author":"Lebret","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0085","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00345-023-04519-4","article-title":"Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial","volume":"41","author":"Lebret","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0086","article-title":"A deep learning system to predict the histopathological results from urine cytopathological images","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.02.009_bib0087","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cncy.22443","article-title":"A deep learning system to diagnose the malignant potential of urothelial carcinoma cells in cytology specimens","volume":"129","author":"Nojima","year":"2021","journal-title":"Cancer Cytopathol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:27:44Z","timestamp":1757338064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1078143925000377"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular testing in urinary cytology specimens: Current status and future directions","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}